Skip to main content
NewslettersWatchlist

Alimera Sciences Inc(ALIM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.51
Day High3.59
Open:3.55
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Globe Newswire
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Globe Newswire
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
Globe Newswire
Alimera Sciences Announces Second Quarter 2022 Financial Results
Globe Newswire
Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress
Globe Newswire
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
Globe Newswire
Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant
Globe Newswire
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
Globe Newswire
Alimera Sciences Reports First Quarter 2022 Results
Globe Newswire
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
Globe Newswire
Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress
Globe Newswire
Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation
Globe Newswire
Alimera Sciences Reports Fourth Quarter and FY 2021 Results
Globe Newswire
Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
Globe Newswire
Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update
Globe Newswire
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
AccessWire
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
Globe Newswire
Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences
Globe Newswire
Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors
Investor Brand Network
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
Globe Newswire
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
Globe Newswire
Alimera Sciences Announces Third Quarter 2021 Financial Results
Globe Newswire
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
Globe NewsWire
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
Globe NewsWire
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
Globe NewsWire
Alimera Sciences Announces Second Quarter 2021 Financial Results
Globe NewsWire
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
Globe NewsWire
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
AccessWire
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
Globe NewsWire
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
Globe NewsWire
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
Globe NewsWire
Alimera Sciences Announces First Quarter 2021 Financial Results
Globe NewsWire
Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update

Profile

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.